How Do You Know It’s Psoriasis? Here Are The Signs And Symptoms You Should Look For
More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...
Pharmaceutical Technology14d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...
The American Journal of Managed Care14d
GPP Flares Linked to Increased Hospitalizations, Health Care Costs, Study Finds
New research highlights the significant health care resource utilization burden of generalized pustular psoriasis (GPP), revealing higher hospitalizations and costs among patients experiencing flares.
Le Lézard13d
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue.1,2,3,4SPEVIGO's ...
Vanda Pharmaceuticals And Anaptys Announce Exclusive Global License Agreement For Vanda To Develop And Commercialize Imsidolimab, An IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular Psoriasis <li /> Vanda expects to immediately ...
Hosted on MSN14d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
to treat the severe skin disorder generalised pustular psoriasis (GPP). The agreement follows the completion of two Phase III trials, GEMINI-1 and GEMINI-2, which assessed the efficacy and safety ...
D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Contract Pharma15d
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.